Table of Content

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Mice Model Generation Market

4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Mice Model Generation Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights
5.1. Global Genetically Engineered Mouse Model Overview
5.2. Regulatory Scenario by Region/globally
5.3. Technological Advancements
5.4. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)
5.5. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

6. Global Mice Model Generation Market Analysis and Forecast, by Technology
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Technology, 2017–2031
6.3.1. CRISPR Knockout
6.3.2. CRISPR Knockin
6.3.3. Random Insertions
6.3.4. Large, Targeted Insertions
6.3.5. ES Cell Modification (homologous recombination)
6.3.6. Others
6.4. Market Attractiveness Analysis, by Technology

7. Global Mice Model Generation Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by End-user, 2017–2031
7.3.1. Pharmaceutical Companies
7.3.2. Biotechnology Companies
7.3.3. Academic & Research Facilities
7.3.4. Contract Research & Manufacturing Organizations
7.4. Market Attractiveness Analysis, by End-user

8. Global Mice Model Generation Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region

9. North America Mice Model Generation Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Technology, 2017–2031
9.2.1. CRISPR Knockout
9.2.2. CRISPR Knockin
9.2.3. Random Insertions
9.2.4. Large, Targeted Insertions
9.2.5. ES Cell Modification (homologous recombination)
9.2.6. Others
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Pharmaceutical Companies
9.3.2. Biotechnology Companies
9.3.3. Academic & Research Facilities
9.3.4. Contract Research & Manufacturing Organizations
9.4. Market Value Forecast, by End-user by Technology, 2017–2031
9.4.1. Pharmaceutical Companies
9.4.1.1. CRISPR Knockout
9.4.1.2. CRISPR Knockin
9.4.1.3. Random Insertions
9.4.1.4. Large, Targeted Insertions
9.4.1.5. ES Cell Modification (homologous recombination)
9.4.1.6. Others
9.4.2. Biotechnology Companies
9.4.2.1. CRISPR Knockout
9.4.2.2. CRISPR Knockin
9.4.2.3. Random Insertions
9.4.2.4. Large, Targeted Insertions
9.4.2.5. ES Cell Modification (homologous recombination)
9.4.2.6. Others
9.4.3. Academic & Research Facilities
9.4.3.1. CRISPR Knockout
9.4.3.2. CRISPR Knockin
9.4.3.3. Random Insertions
9.4.3.4. Large, Targeted Insertions
9.4.3.5. ES Cell Modification (homologous recombination)
9.4.3.6. Others
9.4.4. Contract Research & Manufacturing Organizations
9.4.4.1. CRISPR Knockout
9.4.4.2. CRISPR Knockin
9.4.4.3. Random Insertions
9.4.4.4. Large, Targeted Insertions
9.4.4.5. ES Cell Modification (homologous recombination)
9.4.4.6. Others
9.5. Market Value Forecast, by Country, 2017–2031
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Technology
9.6.2. By End-user
9.6.3. By End-user by Technology
9.6.4. By Country

10. Europe Mice Model Generation Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Technology, 2017–2031
10.2.1. CRISPR Knockout
10.2.2. CRISPR Knockin
10.2.3. Random Insertions
10.2.4. Large, Targeted Insertions
10.2.5. ES Cell Modification (homologous recombination)
10.2.6. Others
10.3. Market Value Forecast, by End-user, 2017–2031
10.3.1. Pharmaceutical Companies
10.3.2. Biotechnology Companies
10.3.3. Academic & Research Facilities
10.3.4. Contract Research & Manufacturing Organizations
10.4. Market Value Forecast, by End-user by Technology, 2017–2031
10.4.1. Pharmaceutical Companies
10.4.1.1. CRISPR Knockout
10.4.1.2. CRISPR Knockin
10.4.1.3. Random Insertions
10.4.1.4. Large, Targeted Insertions
10.4.1.5. ES Cell Modification (homologous recombination)
10.4.1.6. Others
10.4.2. Biotechnology Companies
10.4.2.1. CRISPR Knockout
10.4.2.2. CRISPR Knockin
10.4.2.3. Random Insertions
10.4.2.4. Large, Targeted Insertions
10.4.2.5. ES Cell Modification (homologous recombination)
10.4.2.6. Others
10.4.3. Academic & Research Facilities
10.4.3.1. CRISPR Knockout
10.4.3.2. CRISPR Knockin
10.4.3.3. Random Insertions
10.4.3.4. Large, Targeted Insertions
10.4.3.5. ES Cell Modification (homologous recombination)
10.4.3.6. Others
10.4.4. Contract Research & Manufacturing Organizations
10.4.4.1. CRISPR Knockout
10.4.4.2. CRISPR Knockin
10.4.4.3. Random Insertions
10.4.4.4. Large, Targeted Insertions
10.4.4.5. ES Cell Modification (homologous recombination)
10.4.4.6. Others
10.5. Market Value Forecast, by Country/Sub-region, 2017–2031
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Spain
10.5.5. Italy
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Technology
10.6.2. By End-user
10.6.3. By End-user by Technology
10.6.4. By Country/Sub-region
11. Asia Pacific Mice Model Generation Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Technology, 2017–2031
11.2.1. CRISPR Knockout
11.2.2. CRISPR Knockin
11.2.3. Random Insertions
11.2.4. Large, Targeted Insertions
11.2.5. ES Cell Modification (homologous recombination)
11.2.6. Others
11.3. Market Value Forecast, by End-user, 2017–2031
11.3.1. Pharmaceutical Companies
11.3.2. Biotechnology Companies
11.3.3. Academic & Research Facilities
11.3.4. Contract Research & Manufacturing Organizations
11.4. Market Value Forecast, by End-user by Technology, 2017–2031
11.4.1. Pharmaceutical Companies
11.4.1.1. CRISPR Knockout
11.4.1.2. CRISPR Knockin
11.4.1.3. Random Insertions
11.4.1.4. Large, Targeted Insertions
11.4.1.5. ES Cell Modification (homologous recombination)
11.4.1.6. Others
11.4.2. Biotechnology Companies
11.4.2.1. CRISPR Knockout
11.4.2.2. CRISPR Knockin
11.4.2.3. Random Insertions
11.4.2.4. Large, Targeted Insertions
11.4.2.5. ES Cell Modification (homologous recombination)
11.4.2.6. Others
11.4.3. Academic & Research Facilities
11.4.3.1. CRISPR Knockout
11.4.3.2. CRISPR Knockin
11.4.3.3. Random Insertions
11.4.3.4. Large, Targeted Insertions
11.4.3.5. ES Cell Modification (homologous recombination)
11.4.3.6. Others
11.4.4. Contract Research & Manufacturing Organizations
11.4.4.1. CRISPR Knockout
11.4.4.2. CRISPR Knockin
11.4.4.3. Random Insertions
11.4.4.4. Large, Targeted Insertions
11.4.4.5. ES Cell Modification (homologous recombination)
11.4.4.6. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Technology
11.6.2. By End-user
11.6.3. By End-user by Technology
11.6.4. By Country/Sub-region

12. Latin America Mice Model Generation Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Technology, 2017–2031
12.2.1. CRISPR Knockout
12.2.2. CRISPR Knockin
12.2.3. Random Insertions
12.2.4. Large, Targeted Insertions
12.2.5. ES Cell Modification (homologous recombination)
12.2.6. Others
12.3. Market Value Forecast, by End-user, 2017–2031
12.3.1. Pharmaceutical Companies
12.3.2. Biotechnology Companies
12.3.3. Academic & Research Facilities
12.3.4. Contract Research & Manufacturing Organizations
12.4. Market Value Forecast, by End-user by Technology, 2017–2031
12.4.1. Pharmaceutical Companies
12.4.1.1. CRISPR Knockout
12.4.1.2. CRISPR Knockin
12.4.1.3. Random Insertions
12.4.1.4. Large, Targeted Insertions
12.4.1.5. ES Cell Modification (homologous recombination)
12.4.1.6. Others
12.4.2. Biotechnology Companies
12.4.2.1. CRISPR Knockout
12.4.2.2. CRISPR Knockin
12.4.2.3. Random Insertions
12.4.2.4. Large, Targeted Insertions
12.4.2.5. ES Cell Modification (homologous recombination)
12.4.2.6. Others
12.4.3. Academic & Research Facilities
12.4.3.1. CRISPR Knockout
12.4.3.2. CRISPR Knockin
12.4.3.3. Random Insertions
12.4.3.4. Large, Targeted Insertions
12.4.3.5. ES Cell Modification (homologous recombination)
12.4.3.6. Others
12.4.4. Contract Research & Manufacturing Organizations
12.4.4.1. CRISPR Knockout
12.4.4.2. CRISPR Knockin
12.4.4.3. Random Insertions
12.4.4.4. Large, Targeted Insertions
12.4.4.5. ES Cell Modification (homologous recombination)
12.4.4.6. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Technology
12.6.2. By End-user
12.6.3. By End-user by Technology
12.6.4. By Country/Sub-region

13. Middle East & Africa Mice Model Generation Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Technology, 2017–2031
13.2.1. CRISPR Knockout
13.2.2. CRISPR Knockin
13.2.3. Random Insertions
13.2.4. Large, Targeted Insertions
13.2.5. ES Cell Modification (homologous recombination)
13.2.6. Others
13.3. Market Value Forecast, by End-user, 2017–2031
13.3.1. Pharmaceutical Companies
13.3.2. Biotechnology Companies
13.3.3. Academic & Research Facilities
13.3.4. Contract Research & Manufacturing Organizations
13.4. Market Value Forecast, by End-user by Technology, 2017–2031
13.4.1. Pharmaceutical Companies
13.4.1.1. CRISPR Knockout
13.4.1.2. CRISPR Knockin
13.4.1.3. Random Insertions
13.4.1.4. Large, Targeted Insertions
13.4.1.5. ES Cell Modification (homologous recombination)
13.4.1.6. Others
13.4.2. Biotechnology Companies
13.4.2.1. CRISPR Knockout
13.4.2.2. CRISPR Knockin
13.4.2.3. Random Insertions
13.4.2.4. Large, Targeted Insertions
13.4.2.5. ES Cell Modification (homologous recombination)
13.4.2.6. Others
13.4.3. Academic & Research Facilities
13.4.3.1. CRISPR Knockout
13.4.3.2. CRISPR Knockin
13.4.3.3. Random Insertions
13.4.3.4. Large, Targeted Insertions
13.4.3.5. ES Cell Modification (homologous recombination)
13.4.3.6. Others
13.4.4. Contract Research & Manufacturing Organizations
13.4.4.1. CRISPR Knockout
13.4.4.2. CRISPR Knockin
13.4.4.3. Random Insertions
13.4.4.4. Large, Targeted Insertions
13.4.4.5. ES Cell Modification (homologous recombination)
13.4.4.6. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
13.6.1. By Technology
13.6.2. By End-user
13.6.3. By End-user by Technology
13.6.4. By Country/Sub-region

14. Competition Landscape
14.1. Market Player - Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2021
14.2.1. Global
14.2.2. North America
14.2.3. Europe
14.2.4. By Asia Pacific
14.2.5. By Latin America
14.2.6. By Middle East & Africa
14.3. Company Profiles
14.3.1. Biocytogen
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Strategic Overview
14.3.2. Charles River Laboratories
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Strategic Overview
14.3.3. Cyagen Biosciences
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Strategic Overview
14.3.4. Gempharmatech
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Strategic Overview
14.3.5. genOway
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Strategic Overview
14.3.6. ingenious targeting laboratory
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Strategic Overview
14.3.7. Merck KGaA
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Strategic Overview
14.3.8. Ozgene Pty Ltd.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Strategic Overview
14.3.9. Taconic Biosciences, Inc.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Strategic Overview
14.3.10. PolyGene AG
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Product Portfolio
14.3.10.3. SWOT Analysis
14.3.10.4. Strategic Overview
14.3.11. The Jackson Laboratory
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Product Portfolio
14.3.11.3. SWOT Analysis
14.3.11.4. Strategic Overview
14.3.12. Yale School of Medicine
14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.12.2. Product Portfolio
14.3.12.3. SWOT Analysis
14.3.12.4. Strategic Overview
14.3.13. University of North Carolina
14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.13.2. Product Portfolio
14.3.13.3. SWOT Analysis
14.3.13.4. Strategic Overview
14.3.14. University of Nebraska Medical Center
14.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.14.2. Product Portfolio
14.3.14.3. SWOT Analysis
14.3.14.4. Strategic Overview
14.3.15. Monash University
14.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.15.2. Product Portfolio
14.3.15.3. SWOT Analysis
14.3.15.4. Strategic Overview
14.3.16. UMass Chan Medical School
14.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.16.2. Product Portfolio
14.3.16.3. SWOT Analysis
14.3.16.4. Strategic Overview
14.3.17. University of Bonn
14.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.17.2. Product Portfolio
14.3.17.3. SWOT Analysis
14.3.17.4. Strategic Overview
14.3.18. Columbia University
14.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.18.2. Product Portfolio
14.3.18.3. SWOT Analysis
14.3.18.4. Strategic Overview
14.3.19. The University of Arizona
14.3.19.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.19.2. Product Portfolio
14.3.19.3. SWOT Analysis
14.3.19.4. Strategic Overview
14.3.20. Hadassah BrainLabs
14.3.20.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.20.2. Product Portfolio
14.3.20.3. SWOT Analysis
14.3.20.4. Strategic Overview
14.3.21. The Weizmann Institute of Science
14.3.21.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.21.2. Product Portfolio
14.3.21.3. SWOT Analysis
14.3.21.4. Strategic Overview
14.3.22. The Hebrew University of Jerusalem
14.3.22.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.22.2. Product Portfolio
14.3.22.3. SWOT Analysis
14.3.22.4. Strategic Overview
14.3.23. The Technion – Israel Institute of Technology
14.3.23.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.23.2. Product Portfolio
14.3.23.3. SWOT Analysis
14.3.23.4. Strategic Overview



List of Figures

List of Figures

Figure 01: Global Mice Model Generation Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Global Mice Model Generation Market Value Share, by Technology, 2021

Figure 03: Global Mice Model Generation Market Value Share, by End-user, 2021

Figure 04: Global Mice Model Generation Market Value Share, by Region, 2021

Figure 05: Global Mice Model Generation Market Value Share Analysis, by Technology, 2021 and 2031

Figure 06: Global Mice Model Generation Market Attractiveness Analysis, by Technology, 2022–2031

Figure 07: Global Mice Model Generation Market Value (US$ Mn), by CRISPR Knockout, 2017?2031

Figure 08: Global Mice Model Generation Market Value (US$ Mn), by CRISPR Knockin Mice, 2017?2031

Figure 09: Global Mice Model Generation Market Value (US$ Mn), by Random Insertions, 2017?2031

Figure 10: Global Mice Model Generation Market Value (US$ Mn), by Large, Targeted Insertions, 2017?2031

Figure 11: Global Mice Model Generation Market Value (US$ Mn), by ES Cell Modification (homologous recombination), 2017?2031

Figure 12: Global Mice Model Generation Market Value (US$ Mn), by Others, 2017?2031

Figure 13: Global Mice Model Generation Market Value Share Analysis, by End-user, 2021 and 2031

Figure 14: Global Mice Model Generation Market Attractiveness Analysis, by End-user, 2022–2031

Figure 15: Global Mice Model Generation Market Value (US$ Mn), by Pharmaceutical Companies, 2017?2031

Figure 16: Global Mice Model Generation Market Value (US$ Mn), by Biotechnology Companies, 2017?2031

Figure 17: Global Mice Model Generation Market Value (US$ Mn), by Academic & Research Facilities, 2017?2031

Figure 18: Global Mice Model Generation Market Value (US$ Mn), by Contract Research & Manufacturing Organizations, 2017?2031

Figure 19: Global Mice Model Generation Market Value Share Analysis, by Region, 2021 and 2031

Figure 20: Global Mice Model Generation Market Attractiveness Analysis, by Region, 2022–2031

Figure 21: North America Mice Model Generation Market Value (US$ Mn) Forecast, 2017–2031

Figure 23: North America Mice Model Generation Market Attractiveness Analysis, by Country, 2022–2031

Figure 22: North America Mice Model Generation Market Value Share Analysis, by Country, 2021 and 2031

Figure 24: North America Mice Model Generation Market Value Share Analysis, by Technology, 2021 and 2031

Figure 25: North America Mice Model Generation Market Attractiveness Analysis, by Technology, 2022–2031

Figure 26: North America Mice Model Generation Market Value Share Analysis, by End-user, 2021 and 2031

Figure 27: North America Mice Model Generation Market Attractiveness Analysis, by End-user, 2022–2031

Figure 28: Europe Mice Model Generation Market Value (US$ Mn) Forecast, 2017–2031

Figure 30: Europe Mice Model Generation Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 29: Europe Mice Model Generation Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 31: Europe Mice Model Generation Market Value Share Analysis, by Technology, 2021 and 2031

Figure 32: Europe Mice Model Generation Market Attractiveness Analysis, by Technology, 2022–2031

Figure 33: Europe Mice Model Generation Market Value Share Analysis, by End-user, 2021 and 2031

Figure 34: Europe Mice Model Generation Market Attractiveness Analysis, by End-user, 2022–2031

Figure 35: Asia Pacific Mice Model Generation Market Value (US$ Mn) Forecast, 2017–2031

Figure 37: Asia Pacific Mice Model Generation Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 36: Asia Pacific Mice Model Generation Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 38: Asia Pacific Mice Model Generation Market Value Share Analysis, by Technology, 2021 and 2031

Figure 39: Asia Pacific Mice Model Generation Market Attractiveness Index, by Technology, 2022–2031

Figure 40: Asia Pacific Mice Model Generation Market Value Share Analysis, by End-user, 2021 and 2031

Figure 41: Asia Pacific Mice Model Generation Market Attractiveness Analysis, by End-user, 2022–2031

Figure 42: Latin America Mice Model Generation Market Value (US$ Mn) Forecast, 2017–2031

Figure 44: Latin America Mice Model Generation Market Attractiveness Analysis, by Country/Sub-region, 2021-2031

Figure 43: Latin America Mice Model Generation Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 45: Latin America Mice Model Generation Market Value Share Analysis, by Technology, 2021 and 2031

Figure 46: Latin America Mice Model Generation Market Attractiveness Analysis, by Technology, 2022–2031

Figure 47: Latin America Mice Model Generation Market Value Share Analysis, by End-user, 2021 and 2031

Figure 48: Latin America Mice Model Generation Market Attractiveness Analysis, by End-user, 2022–2031

Figure 49: Middle East & Africa Mice Model Generation Market Value (US$ Mn) Forecast, 2017–2031

Figure 51: Middle East & Africa Mice Model Generation Market Attractiveness Analysis, by Country/Sub-region, 2021-2031

Figure 50: Middle East & Africa Mice Model Generation Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 52: Middle East & Africa Mice Model Generation Market Value Share Analysis, by Technology, 2021 and 2031

Figure 53: Middle East & Africa Mice Model Generation Market Attractiveness Analysis, by Technology, 2022–2031

Figure 54: Middle East & Africa Mice Model Generation Market Value Share Analysis, by End-user, 2021 and 2031

Figure 55: Middle East & Africa Mice Model Generation Market Attractiveness Analysis, by End-user, 2022–2031

List of Tables

List of Tables

Table 01: Price/Cost Analysis of Mice Models, by Region

Table 02: Global Mice Model Generation Market Value (US$ Mn) Forecast, by Technology, 2017?2031

Table 03: Global Mice Model Generation Market Value (US$ Mn) Forecast, by End-user, 2017?2031

Table 04: Global Mice Model Generation Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017?2031

Table 05: Global Mice Model Generation Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017?2031

Table 06: Global Mice Model Generation Market Value (US$ Mn) Forecast, Academic & Research Facilities by Technology, 2017?2031

Table 07: Global Mice Model Generation Market Value (US$ Mn) Forecast, Contract Research & Manufacturing Organizations by Technology, 2017?2031

Table 08: Global Mice Model Generation Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 09: North America Mice Model Generation Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 10: North America Mice Model Generation Market Value (US$ Mn) Forecast, by Technology, 2017?2031

Table 11: North America Mice Model Generation Market Value (US$ Mn) Forecast, by End-user, 2017?2031

Table 12: North America Mice Model Generation Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017?2031

Table 13: North America Mice Model Generation Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017?2031

Table 14: North America Mice Model Generation Market Value (US$ Mn) Forecast, Academic & Research Facilities by Technology, 2017?2031

Table 15: North America Mice Model Generation Market Value (US$ Mn) Forecast, Contract Research & Manufacturing Organizations by Technology, 2017?2031

Table 16: Europe Mice Model Generation Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 17: Europe Mice Model Generation Market Value (US$ Mn) Forecast, by Technology, 2017?2031

Table 18: Europe Mice Model Generation Market Value (US$ Mn) Forecast, by End-user, 2017?2031

Table 19: Europe Mice Model Generation Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017?2031

Table 20: Europe Mice Model Generation Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017?2031

Table 21: Europe Mice Model Generation Market Value (US$ Mn) Forecast, Academic & Research Facilities by Technology, 2017?2031

Table 22: Europe Mice Model Generation Market Value (US$ Mn) Forecast, Contract Research & Manufacturing Organizations by Technology, 2017?2031

Table 23: Asia Pacific Mice Model Generation Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 24: Asia Pacific Mice Model Generation Market Value (US$ Mn) Forecast, by Technology, 2017?2031

Table 25: Asia Pacific Mice Model Generation Market Value (US$ Mn) Forecast, by End-user, 2017?2031

Table 26: Asia Pacific Mice Model Generation Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017?2031

Table 27: Asia Pacific Mice Model Generation Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017?2031

Table 28: Asia Pacific Mice Model Generation Market Value (US$ Mn) Forecast, Academic & Research Facilities by Technology, 2017?2031

Table 29: Asia Pacific Mice Model Generation Market Value (US$ Mn) Forecast, Contract Research & Manufacturing Organizations by Technology, 2017?2031

Table 30: Latin America Mice Model Generation Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 31: Latin America Mice Model Generation Market Value (US$ Mn) Forecast, by Technology, 2017?2031

Table 32: Latin America Mice Model Generation Market Value (US$ Mn) Forecast, by End-user, 2017?2031

Table 33: Latin America Mice Model Generation Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017?2031

Table 34: Latin America Mice Model Generation Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017?2031

Table 35: Latin America Mice Model Generation Market Value (US$ Mn) Forecast, Academic & Research Facilities by Technology, 2017?2031

Table 36: Latin America Mice Model Generation Market Value (US$ Mn) Forecast, Contract Research & Manufacturing Organizations by Technology, 2017?2031

Table 37: Middle East & Africa Mice Model Generation Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 38: Middle East & Africa Mice Model Generation Market Value (US$ Mn) Forecast, by Technology, 2017?2031

Table 39: Middle East & Africa Mice Model Generation Market Value (US$ Mn) Forecast, by End-user, 2017?2031

Table 40: Middle East & Africa Mice Model Generation Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017?2031

Table 41: Middle East & Africa Mice Model Generation Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017?2031

Table 42: Middle East & Africa Mice Model Generation Market Value (US$ Mn) Forecast, Academic & Research Facilities by Technology, 2017?2031

Table 43: Middle East & Africa Mice Model Generation Market Value (US$ Mn) Forecast, Contract Research & Manufacturing Organizations by Technology, 2017?2031